Stock Track | Corvus Pharmaceuticals Plummets 5.18% Intraday on Expanded Stock Sale Agreement

Stock Track03-13

Corvus Pharmaceuticals' stock plummeted 5.18% during intraday trading on Friday, driven by news of an expanded stock sale program.

The biotech company amended its sales agreement with Jefferies to sell up to $200 million of common stock, doubling the previous $100 million limit established in 2024. The amended agreement allows Corvus to sell shares through various methods, including private placements and block trades, with Jefferies entitled to a commission of up to 3% on gross sales.

This significant increase in potential share issuance raised investor concerns about dilution and future selling pressure, leading to the stock's decline. The company had not sold any shares under the prior agreement, according to regulatory filings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135625797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135625797","market":"hk","top_or_hot":-1,"title":"Stock Track | Corvus Pharmaceuticals Plummets 5.18% Intraday on Expanded Stock Sale Agreement","media":"Stock Track","content":"<p>Corvus Pharmaceuticals' stock plummeted 5.18% during intraday trading on Friday, driven by news of an expanded stock sale program.</p><p>The biotech company amended its sales agreement with Jefferies to sell up to $200 million of common stock, doubling the previous $100 million limit established in 2024. The amended agreement allows Corvus to sell shares through various methods, including private placements and block trades, with Jefferies entitled to a commission of up to 3% on gross sales.</p><p>This significant increase in potential share issuance raised investor concerns about dilution and future selling pressure, leading to the stock's decline. The company had not sold any shares under the prior agreement, according to regulatory filings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corvus Pharmaceuticals Plummets 5.18% Intraday on Expanded Stock Sale Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corvus Pharmaceuticals Plummets 5.18% Intraday on Expanded Stock Sale Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-13 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corvus Pharmaceuticals' stock plummeted 5.18% during intraday trading on Friday, driven by news of an expanded stock sale program.</p><p>The biotech company amended its sales agreement with Jefferies to sell up to $200 million of common stock, doubling the previous $100 million limit established in 2024. The amended agreement allows Corvus to sell shares through various methods, including private placements and block trades, with Jefferies entitled to a commission of up to 3% on gross sales.</p><p>This significant increase in potential share issuance raised investor concerns about dilution and future selling pressure, leading to the stock's decline. The company had not sold any shares under the prior agreement, according to regulatory filings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1135625797","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135625797","pubTimestamp":1773414311,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corvus Pharmaceuticals' stock plummeted 5.18% during intraday trading on Friday, driven by news of an expanded stock sale program.The biotech company amended its sales agreement with Jefferies to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"个股追踪|Corvus制药盘中暴跌5.18%股票出售协议扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"Corvus Pharmaceuticals' stock plummeted 5.18% during intraday trading on Friday, driven by news of an expanded stock sale program.The biotech company amended its sales agreement with Jefferies to sell up to $200 million of common stock, doubling the previous $100 million limit established in 2024. The amended agreement allows Corvus to sell shares through various methods, including private placements and block trades, with Jefferies entitled to a commission of up to 3% on gross sales.This significant increase in potential share issuance raised investor concerns about dilution and future selling pressure, leading to the stock's decline. The company had not sold any shares under the prior agreement, according to regulatory filings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135625797","isCrawlerRequest":true}